Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P48637
UPID:
GSHB_HUMAN
Alternative names:
Glutathione synthase
Alternative UPACC:
P48637; B2R697; B6F210; E1P5P9; Q4TTD9
Background:
Glutathione synthetase, encoded by the gene with accession number P48637, plays a pivotal role in cellular defense mechanisms. It catalyzes the synthesis of glutathione, a crucial antioxidant that protects cells from oxidative damage, supports amino acid transport, detoxifies foreign substances, maintains protein sulfhydryl groups, and serves as an enzyme cofactor. This protein's activity is essential for maintaining cellular health and homeostasis.
Therapeutic significance:
Glutathione synthetase deficiency, including its severe form leading to increased hemolysis and central nervous system dysfunction, and a milder form causing hemolytic anemia, underscores the protein's critical role in human health. Targeting the pathways involving glutathione synthetase could offer novel therapeutic strategies for these conditions.